{
  "name": "Adverse events in human trials of research peptides",
  "description": "Adverse event and discontinuation rates by arm, with the comparator's rate, for every trial in the trials dataset that reports them.",
  "source": "https://www.primaralabs.com/research/trials",
  "lastUpdated": "2026-09-23",
  "licence": "Free to reuse with a link to the source page.",
  "schema": [
    {
      "key": "trial",
      "type": "string",
      "description": "Trial name."
    },
    {
      "key": "trialSlug",
      "type": "string",
      "description": "Page at /research/trials/<slug>."
    },
    {
      "key": "compound",
      "type": "string",
      "description": "Compound studied."
    },
    {
      "key": "event",
      "type": "string",
      "description": "Adverse event, or discontinuation for adverse events."
    },
    {
      "key": "arm",
      "type": "string",
      "description": "Arm label."
    },
    {
      "key": "pct",
      "type": "number",
      "description": "Share of the arm with the event."
    },
    {
      "key": "comparator",
      "type": "string",
      "description": "Placebo or the named comparator."
    },
    {
      "key": "comparatorPct",
      "type": "number",
      "description": "Share of the comparator arm with the event."
    },
    {
      "key": "sourceUrl",
      "type": "url",
      "description": "The primary source the row was read from."
    },
    {
      "key": "checkedOn",
      "type": "date",
      "description": "ISO date the source was last read."
    }
  ],
  "rowCount": 122,
  "rows": [
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Discontinuation for adverse events",
      "arm": "4 mg",
      "pct": 4.1,
      "comparator": "Placebo",
      "comparatorPct": 4.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Discontinuation for adverse events",
      "arm": "9 mg",
      "pct": 6.9,
      "comparator": "Placebo",
      "comparatorPct": 4.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Discontinuation for adverse events",
      "arm": "12 mg",
      "pct": 11.3,
      "comparator": "Placebo",
      "comparatorPct": 4.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Nausea",
      "arm": "4 mg",
      "pct": 28.6,
      "comparator": "Placebo",
      "comparatorPct": 14.8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Nausea",
      "arm": "9 mg",
      "pct": 38.4,
      "comparator": "Placebo",
      "comparatorPct": 14.8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Nausea",
      "arm": "12 mg",
      "pct": 42.4,
      "comparator": "Placebo",
      "comparatorPct": 14.8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Diarrhoea",
      "arm": "4 mg",
      "pct": 25.2,
      "comparator": "Placebo",
      "comparatorPct": 13.5,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Diarrhoea",
      "arm": "9 mg",
      "pct": 34.1,
      "comparator": "Placebo",
      "comparatorPct": 13.5,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Diarrhoea",
      "arm": "12 mg",
      "pct": 32,
      "comparator": "Placebo",
      "comparatorPct": 13.5,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Constipation",
      "arm": "4 mg",
      "pct": 23.8,
      "comparator": "Placebo",
      "comparatorPct": 10.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Constipation",
      "arm": "9 mg",
      "pct": 25.9,
      "comparator": "Placebo",
      "comparatorPct": 10.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Constipation",
      "arm": "12 mg",
      "pct": 26.1,
      "comparator": "Placebo",
      "comparatorPct": 10.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Vomiting",
      "arm": "4 mg",
      "pct": 10.6,
      "comparator": "Placebo",
      "comparatorPct": 4.8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Vomiting",
      "arm": "9 mg",
      "pct": 22.8,
      "comparator": "Placebo",
      "comparatorPct": 4.8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Vomiting",
      "arm": "12 mg",
      "pct": 25.3,
      "comparator": "Placebo",
      "comparatorPct": 4.8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Dysesthesia",
      "arm": "4 mg",
      "pct": 5.1,
      "comparator": "Placebo",
      "comparatorPct": 0.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Dysesthesia",
      "arm": "9 mg",
      "pct": 12.3,
      "comparator": "Placebo",
      "comparatorPct": 0.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Dysesthesia",
      "arm": "12 mg",
      "pct": 12.5,
      "comparator": "Placebo",
      "comparatorPct": 0.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Urinary tract infection",
      "arm": "4 mg",
      "pct": 7.5,
      "comparator": "Placebo",
      "comparatorPct": 5.3,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Urinary tract infection",
      "arm": "9 mg",
      "pct": 8.8,
      "comparator": "Placebo",
      "comparatorPct": 5.3,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-1",
      "trialSlug": "triumph-1",
      "compound": "Retatrutide",
      "event": "Urinary tract infection",
      "arm": "12 mg",
      "pct": 8.4,
      "comparator": "Placebo",
      "comparatorPct": 5.3,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Discontinuation for adverse events",
      "arm": "4 mg",
      "pct": 3.8,
      "comparator": "Placebo",
      "comparatorPct": 4.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Discontinuation for adverse events",
      "arm": "9 mg",
      "pct": 11.6,
      "comparator": "Placebo",
      "comparatorPct": 4.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Discontinuation for adverse events",
      "arm": "12 mg",
      "pct": 7.7,
      "comparator": "Placebo",
      "comparatorPct": 4.9,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Diarrhoea",
      "arm": "4 mg",
      "pct": 27.4,
      "comparator": "Placebo",
      "comparatorPct": 13.2,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Diarrhoea",
      "arm": "9 mg",
      "pct": 33.5,
      "comparator": "Placebo",
      "comparatorPct": 13.2,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Diarrhoea",
      "arm": "12 mg",
      "pct": 33.6,
      "comparator": "Placebo",
      "comparatorPct": 13.2,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Nausea",
      "arm": "4 mg",
      "pct": 13.7,
      "comparator": "Placebo",
      "comparatorPct": 8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Nausea",
      "arm": "9 mg",
      "pct": 20.8,
      "comparator": "Placebo",
      "comparatorPct": 8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Nausea",
      "arm": "12 mg",
      "pct": 28,
      "comparator": "Placebo",
      "comparatorPct": 8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Constipation",
      "arm": "4 mg",
      "pct": 14,
      "comparator": "Placebo",
      "comparatorPct": 9.4,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Constipation",
      "arm": "9 mg",
      "pct": 16.2,
      "comparator": "Placebo",
      "comparatorPct": 9.4,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Constipation",
      "arm": "12 mg",
      "pct": 16.8,
      "comparator": "Placebo",
      "comparatorPct": 9.4,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Decreased appetite",
      "arm": "4 mg",
      "pct": 5.8,
      "comparator": "Placebo",
      "comparatorPct": 4.5,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Decreased appetite",
      "arm": "9 mg",
      "pct": 12.3,
      "comparator": "Placebo",
      "comparatorPct": 4.5,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Decreased appetite",
      "arm": "12 mg",
      "pct": 17.1,
      "comparator": "Placebo",
      "comparatorPct": 4.5,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Vomiting",
      "arm": "4 mg",
      "pct": 5.5,
      "comparator": "Placebo",
      "comparatorPct": 4.2,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Vomiting",
      "arm": "9 mg",
      "pct": 10.2,
      "comparator": "Placebo",
      "comparatorPct": 4.2,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Vomiting",
      "arm": "12 mg",
      "pct": 15.7,
      "comparator": "Placebo",
      "comparatorPct": 4.2,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Dysesthesia",
      "arm": "4 mg",
      "pct": 4.5,
      "comparator": "Placebo",
      "comparatorPct": 0.7,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Dysesthesia",
      "arm": "9 mg",
      "pct": 5.6,
      "comparator": "Placebo",
      "comparatorPct": 0.7,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Dysesthesia",
      "arm": "12 mg",
      "pct": 7.3,
      "comparator": "Placebo",
      "comparatorPct": 0.7,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Urinary tract infection",
      "arm": "4 mg",
      "pct": 3.8,
      "comparator": "Placebo",
      "comparatorPct": 6.6,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Urinary tract infection",
      "arm": "9 mg",
      "pct": 6.3,
      "comparator": "Placebo",
      "comparatorPct": 6.6,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-2",
      "trialSlug": "triumph-2",
      "compound": "Retatrutide",
      "event": "Urinary tract infection",
      "arm": "12 mg",
      "pct": 8,
      "comparator": "Placebo",
      "comparatorPct": 6.6,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Discontinuation for adverse events",
      "arm": "9 mg",
      "pct": 9.8,
      "comparator": "Placebo",
      "comparatorPct": 4.8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Discontinuation for adverse events",
      "arm": "12 mg",
      "pct": 13.5,
      "comparator": "Placebo",
      "comparatorPct": 4.8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Diarrhoea",
      "arm": "9 mg",
      "pct": 30.1,
      "comparator": "Placebo",
      "comparatorPct": 8.7,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Diarrhoea",
      "arm": "12 mg",
      "pct": 24.4,
      "comparator": "Placebo",
      "comparatorPct": 8.7,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Nausea",
      "arm": "9 mg",
      "pct": 21.7,
      "comparator": "Placebo",
      "comparatorPct": 5.8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Nausea",
      "arm": "12 mg",
      "pct": 22.4,
      "comparator": "Placebo",
      "comparatorPct": 5.8,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Constipation",
      "arm": "9 mg",
      "pct": 18,
      "comparator": "Placebo",
      "comparatorPct": 7.1,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Constipation",
      "arm": "12 mg",
      "pct": 15.7,
      "comparator": "Placebo",
      "comparatorPct": 7.1,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Decreased appetite",
      "arm": "9 mg",
      "pct": 13.5,
      "comparator": "Placebo",
      "comparatorPct": 3,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Decreased appetite",
      "arm": "12 mg",
      "pct": 14.5,
      "comparator": "Placebo",
      "comparatorPct": 3,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Dysesthesia",
      "arm": "9 mg",
      "pct": 6.4,
      "comparator": "Placebo",
      "comparatorPct": 1.3,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Dysesthesia",
      "arm": "12 mg",
      "pct": 6.4,
      "comparator": "Placebo",
      "comparatorPct": 1.3,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Urinary tract infection",
      "arm": "9 mg",
      "pct": 6.1,
      "comparator": "Placebo",
      "comparatorPct": 5.3,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-3",
      "trialSlug": "triumph-3",
      "compound": "Retatrutide",
      "event": "Urinary tract infection",
      "arm": "12 mg",
      "pct": 7,
      "comparator": "Placebo",
      "comparatorPct": 5.3,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Discontinuation for adverse events",
      "arm": "9 mg",
      "pct": 12.2,
      "comparator": "Placebo",
      "comparatorPct": 4,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Discontinuation for adverse events",
      "arm": "12 mg",
      "pct": 18.2,
      "comparator": "Placebo",
      "comparatorPct": 4,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Nausea",
      "arm": "9 mg",
      "pct": 38.1,
      "comparator": "Placebo",
      "comparatorPct": 10.7,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Nausea",
      "arm": "12 mg",
      "pct": 43.2,
      "comparator": "Placebo",
      "comparatorPct": 10.7,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Diarrhoea",
      "arm": "9 mg",
      "pct": 34.7,
      "comparator": "Placebo",
      "comparatorPct": 13.4,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Diarrhoea",
      "arm": "12 mg",
      "pct": 33.1,
      "comparator": "Placebo",
      "comparatorPct": 13.4,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Constipation",
      "arm": "9 mg",
      "pct": 21.8,
      "comparator": "Placebo",
      "comparatorPct": 8.7,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Constipation",
      "arm": "12 mg",
      "pct": 25,
      "comparator": "Placebo",
      "comparatorPct": 8.7,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Vomiting",
      "arm": "9 mg",
      "pct": 20.4,
      "comparator": "Placebo",
      "comparatorPct": 0,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Vomiting",
      "arm": "12 mg",
      "pct": 20.9,
      "comparator": "Placebo",
      "comparatorPct": 0,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Decreased appetite",
      "arm": "9 mg",
      "pct": 19,
      "comparator": "Placebo",
      "comparatorPct": 9.4,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Decreased appetite",
      "arm": "12 mg",
      "pct": 18.2,
      "comparator": "Placebo",
      "comparatorPct": 9.4,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Dysesthesia",
      "arm": "9 mg",
      "pct": 8.8,
      "comparator": "Placebo",
      "comparatorPct": 0.7,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "TRIUMPH-4",
      "trialSlug": "triumph-4",
      "compound": "Retatrutide",
      "event": "Dysesthesia",
      "arm": "12 mg",
      "pct": 20.9,
      "comparator": "Placebo",
      "comparatorPct": 0.7,
      "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 2",
      "trialSlug": "step-2",
      "compound": "Semaglutide",
      "event": "Gastrointestinal adverse events",
      "arm": "2.4 mg",
      "pct": 63.5,
      "comparator": "Placebo",
      "comparatorPct": 34.3,
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(21)00213-0",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 2",
      "trialSlug": "step-2",
      "compound": "Semaglutide",
      "event": "Gastrointestinal adverse events",
      "arm": "1.0 mg",
      "pct": 57.5,
      "comparator": "Placebo",
      "comparatorPct": 34.3,
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(21)00213-0",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 3",
      "trialSlug": "step-3",
      "compound": "Semaglutide",
      "event": "Discontinuation for adverse events",
      "arm": "2.4 mg",
      "pct": 5.9,
      "comparator": "Placebo",
      "comparatorPct": 2.9,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.1831",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 3",
      "trialSlug": "step-3",
      "compound": "Semaglutide",
      "event": "Gastrointestinal adverse events",
      "arm": "2.4 mg",
      "pct": 82.8,
      "comparator": "Placebo",
      "comparatorPct": 63.2,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.1831",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 3",
      "trialSlug": "step-3",
      "compound": "Semaglutide",
      "event": "Nausea",
      "arm": "2.4 mg",
      "pct": 58.2,
      "comparator": "Placebo",
      "comparatorPct": 22.1,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.1831",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 3",
      "trialSlug": "step-3",
      "compound": "Semaglutide",
      "event": "Constipation",
      "arm": "2.4 mg",
      "pct": 36.9,
      "comparator": "Placebo",
      "comparatorPct": 24.5,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.1831",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 3",
      "trialSlug": "step-3",
      "compound": "Semaglutide",
      "event": "Diarrhoea",
      "arm": "2.4 mg",
      "pct": 36.1,
      "comparator": "Placebo",
      "comparatorPct": 22.1,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.1831",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 3",
      "trialSlug": "step-3",
      "compound": "Semaglutide",
      "event": "Vomiting",
      "arm": "2.4 mg",
      "pct": 27.3,
      "comparator": "Placebo",
      "comparatorPct": 10.8,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.1831",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 4",
      "trialSlug": "step-4",
      "compound": "Semaglutide",
      "event": "Discontinuation for adverse events",
      "arm": "Continued 2.4 mg, weeks 20 to 68",
      "pct": 2.4,
      "comparator": "Switched to placebo",
      "comparatorPct": 2.2,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.3224",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 4",
      "trialSlug": "step-4",
      "compound": "Semaglutide",
      "event": "Gastrointestinal adverse events",
      "arm": "Continued 2.4 mg, weeks 20 to 68",
      "pct": 41.9,
      "comparator": "Switched to placebo",
      "comparatorPct": 26.1,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.3224",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 4",
      "trialSlug": "step-4",
      "compound": "Semaglutide",
      "event": "Diarrhoea",
      "arm": "Continued 2.4 mg, weeks 20 to 68",
      "pct": 14.4,
      "comparator": "Switched to placebo",
      "comparatorPct": 7.1,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.3224",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 4",
      "trialSlug": "step-4",
      "compound": "Semaglutide",
      "event": "Nausea",
      "arm": "Continued 2.4 mg, weeks 20 to 68",
      "pct": 14,
      "comparator": "Switched to placebo",
      "comparatorPct": 4.9,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.3224",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 4",
      "trialSlug": "step-4",
      "compound": "Semaglutide",
      "event": "Constipation",
      "arm": "Continued 2.4 mg, weeks 20 to 68",
      "pct": 11.6,
      "comparator": "Switched to placebo",
      "comparatorPct": 6.3,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.3224",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 4",
      "trialSlug": "step-4",
      "compound": "Semaglutide",
      "event": "Vomiting",
      "arm": "Continued 2.4 mg, weeks 20 to 68",
      "pct": 10.3,
      "comparator": "Switched to placebo",
      "comparatorPct": 3,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.3224",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 5",
      "trialSlug": "step-5",
      "compound": "Semaglutide",
      "event": "Discontinuation for adverse events",
      "arm": "2.4 mg",
      "pct": 5.9,
      "comparator": "Placebo",
      "comparatorPct": 4.6,
      "sourceUrl": "https://doi.org/10.1038/s41591-022-02026-4",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 5",
      "trialSlug": "step-5",
      "compound": "Semaglutide",
      "event": "Gastrointestinal adverse events",
      "arm": "2.4 mg",
      "pct": 82.2,
      "comparator": "Placebo",
      "comparatorPct": 53.9,
      "sourceUrl": "https://doi.org/10.1038/s41591-022-02026-4",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 5",
      "trialSlug": "step-5",
      "compound": "Semaglutide",
      "event": "Nausea",
      "arm": "2.4 mg",
      "pct": 53.3,
      "comparator": "Placebo",
      "comparatorPct": 21.7,
      "sourceUrl": "https://doi.org/10.1038/s41591-022-02026-4",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 5",
      "trialSlug": "step-5",
      "compound": "Semaglutide",
      "event": "Diarrhoea",
      "arm": "2.4 mg",
      "pct": 34.9,
      "comparator": "Placebo",
      "comparatorPct": 23.7,
      "sourceUrl": "https://doi.org/10.1038/s41591-022-02026-4",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 5",
      "trialSlug": "step-5",
      "compound": "Semaglutide",
      "event": "Constipation",
      "arm": "2.4 mg",
      "pct": 30.9,
      "comparator": "Placebo",
      "comparatorPct": 11.2,
      "sourceUrl": "https://doi.org/10.1038/s41591-022-02026-4",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 5",
      "trialSlug": "step-5",
      "compound": "Semaglutide",
      "event": "Vomiting",
      "arm": "2.4 mg",
      "pct": 30.3,
      "comparator": "Placebo",
      "comparatorPct": 4.6,
      "sourceUrl": "https://doi.org/10.1038/s41591-022-02026-4",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Discontinuation for adverse events",
      "arm": "Semaglutide 2.4 mg",
      "pct": 3.2,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 3.5,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Discontinuation for adverse events",
      "arm": "Liraglutide 3.0 mg",
      "pct": 12.6,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 3.5,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Gastrointestinal disorders",
      "arm": "Semaglutide 2.4 mg",
      "pct": 84.1,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 55.3,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Gastrointestinal disorders",
      "arm": "Liraglutide 3.0 mg",
      "pct": 82.7,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 55.3,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Nausea",
      "arm": "Semaglutide 2.4 mg",
      "pct": 61.1,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 22.4,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Nausea",
      "arm": "Liraglutide 3.0 mg",
      "pct": 59.1,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 22.4,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Constipation",
      "arm": "Semaglutide 2.4 mg",
      "pct": 38.9,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 23.5,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Constipation",
      "arm": "Liraglutide 3.0 mg",
      "pct": 31.5,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 23.5,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Diarrhoea",
      "arm": "Semaglutide 2.4 mg",
      "pct": 27.8,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 25.9,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Diarrhoea",
      "arm": "Liraglutide 3.0 mg",
      "pct": 18.1,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 25.9,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Vomiting",
      "arm": "Semaglutide 2.4 mg",
      "pct": 25.4,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 5.9,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "STEP 8",
      "trialSlug": "step-8",
      "compound": "Semaglutide",
      "event": "Vomiting",
      "arm": "Liraglutide 3.0 mg",
      "pct": 20.5,
      "comparator": "Placebo (pooled)",
      "comparatorPct": 5.9,
      "sourceUrl": "https://doi.org/10.1001/jama.2021.23619",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SELECT",
      "trialSlug": "select",
      "compound": "Semaglutide",
      "event": "Discontinuation for adverse events",
      "arm": "Semaglutide 2.4 mg",
      "pct": 16.6,
      "comparator": "Placebo",
      "comparatorPct": 8.2,
      "sourceUrl": "https://doi.org/10.1056/NEJMoa2307563",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-1",
      "trialSlug": "surmount-1",
      "compound": "Tirzepatide",
      "event": "Discontinuation for adverse events",
      "arm": "5 mg",
      "pct": 4.3,
      "comparator": "Placebo",
      "comparatorPct": 2.6,
      "sourceUrl": "https://doi.org/10.1056/NEJMoa2206038",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-1",
      "trialSlug": "surmount-1",
      "compound": "Tirzepatide",
      "event": "Discontinuation for adverse events",
      "arm": "10 mg",
      "pct": 7.1,
      "comparator": "Placebo",
      "comparatorPct": 2.6,
      "sourceUrl": "https://doi.org/10.1056/NEJMoa2206038",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-1",
      "trialSlug": "surmount-1",
      "compound": "Tirzepatide",
      "event": "Discontinuation for adverse events",
      "arm": "15 mg",
      "pct": 6.2,
      "comparator": "Placebo",
      "comparatorPct": 2.6,
      "sourceUrl": "https://doi.org/10.1056/NEJMoa2206038",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-3",
      "trialSlug": "surmount-3",
      "compound": "Tirzepatide",
      "event": "Discontinuation for adverse events",
      "arm": "Maximum tolerated dose (10 or 15 mg)",
      "pct": 10.5,
      "comparator": "Placebo",
      "comparatorPct": 2.1,
      "sourceUrl": "https://doi.org/10.1038/s41591-023-02597-w",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-3",
      "trialSlug": "surmount-3",
      "compound": "Tirzepatide",
      "event": "Nausea",
      "arm": "Maximum tolerated dose (10 or 15 mg)",
      "pct": 39.7,
      "comparator": "Placebo",
      "comparatorPct": 14,
      "sourceUrl": "https://doi.org/10.1038/s41591-023-02597-w",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-3",
      "trialSlug": "surmount-3",
      "compound": "Tirzepatide",
      "event": "Diarrhoea",
      "arm": "Maximum tolerated dose (10 or 15 mg)",
      "pct": 31,
      "comparator": "Placebo",
      "comparatorPct": 9.2,
      "sourceUrl": "https://doi.org/10.1038/s41591-023-02597-w",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-3",
      "trialSlug": "surmount-3",
      "compound": "Tirzepatide",
      "event": "Constipation",
      "arm": "Maximum tolerated dose (10 or 15 mg)",
      "pct": 23,
      "comparator": "Placebo",
      "comparatorPct": 6.8,
      "sourceUrl": "https://doi.org/10.1038/s41591-023-02597-w",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-3",
      "trialSlug": "surmount-3",
      "compound": "Tirzepatide",
      "event": "Vomiting",
      "arm": "Maximum tolerated dose (10 or 15 mg)",
      "pct": 18.1,
      "comparator": "Placebo",
      "comparatorPct": 1.4,
      "sourceUrl": "https://doi.org/10.1038/s41591-023-02597-w",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-4",
      "trialSlug": "surmount-4",
      "compound": "Tirzepatide",
      "event": "Discontinuation for adverse events",
      "arm": "Continued tirzepatide, weeks 36 to 88",
      "pct": 1.8,
      "comparator": "Switched to placebo",
      "comparatorPct": 0.9,
      "sourceUrl": "https://doi.org/10.1001/jama.2023.24945",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-4",
      "trialSlug": "surmount-4",
      "compound": "Tirzepatide",
      "event": "Diarrhoea",
      "arm": "Continued tirzepatide, weeks 36 to 88",
      "pct": 10.7,
      "comparator": "Switched to placebo",
      "comparatorPct": 4.8,
      "sourceUrl": "https://doi.org/10.1001/jama.2023.24945",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-4",
      "trialSlug": "surmount-4",
      "compound": "Tirzepatide",
      "event": "Nausea",
      "arm": "Continued tirzepatide, weeks 36 to 88",
      "pct": 8.1,
      "comparator": "Switched to placebo",
      "comparatorPct": 2.7,
      "sourceUrl": "https://doi.org/10.1001/jama.2023.24945",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "SURMOUNT-4",
      "trialSlug": "surmount-4",
      "compound": "Tirzepatide",
      "event": "Vomiting",
      "arm": "Continued tirzepatide, weeks 36 to 88",
      "pct": 5.7,
      "comparator": "Switched to placebo",
      "comparatorPct": 1.2,
      "sourceUrl": "https://doi.org/10.1001/jama.2023.24945",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "RECONNECT (studies 301 and 302)",
      "trialSlug": "reconnect",
      "compound": "Bremelanotide",
      "event": "Nausea",
      "arm": "1.75 mg, integrated phase 3",
      "pct": 40,
      "comparator": "Placebo",
      "comparatorPct": 1.3,
      "sourceUrl": "https://doi.org/10.1097/AOG.0000000000003500",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "RECONNECT (studies 301 and 302)",
      "trialSlug": "reconnect",
      "compound": "Bremelanotide",
      "event": "Flushing",
      "arm": "1.75 mg, integrated phase 3",
      "pct": 20.3,
      "comparator": "Placebo",
      "comparatorPct": 1.3,
      "sourceUrl": "https://doi.org/10.1097/AOG.0000000000003500",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "RECONNECT (studies 301 and 302)",
      "trialSlug": "reconnect",
      "compound": "Bremelanotide",
      "event": "Headache",
      "arm": "1.75 mg, integrated phase 3",
      "pct": 11.3,
      "comparator": "Placebo",
      "comparatorPct": 1.9,
      "sourceUrl": "https://doi.org/10.1097/AOG.0000000000003500",
      "checkedOn": "2026-09-23"
    },
    {
      "trial": "RECONNECT (studies 301 and 302)",
      "trialSlug": "reconnect",
      "compound": "Bremelanotide",
      "event": "Injection site reactions",
      "arm": "1.75 mg, integrated phase 3",
      "pct": 5.4,
      "comparator": "Placebo",
      "comparatorPct": 0.5,
      "sourceUrl": "https://doi.org/10.1097/AOG.0000000000003500",
      "checkedOn": "2026-09-23"
    }
  ]
}